Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in Endoscopic Transsphenoidal Tumor Surgery
NCT05005715Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Aug 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexmedetomidine in non-functioning pituitary adenoma (NFPA) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Quality of recovery-15 score. Started Aug 2021; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
non-functioning pituitary adenoma (NFPA)
Beyond the preview
Go deeper on NCT05005715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005715.